Ignite Creation Date:
2025-12-24 @ 1:30 PM
Ignite Modification Date:
2026-01-27 @ 8:34 AM
Study NCT ID:
NCT00301795
Status:
TERMINATED
Last Update Posted:
2013-01-07
First Post:
2006-03-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Stage III Grade 1 Follicular Lymphoma | View |
| None | Stage III Grade 2 Follicular Lymphoma | View |
| None | Stage III Grade 3 Follicular Lymphoma | View |
| None | Stage IV Grade 1 Follicular Lymphoma | View |
| None | Stage IV Grade 2 Follicular Lymphoma | View |
| None | Stage IV Grade 3 Follicular Lymphoma | View |
Keywords: